memantine has been researched along with Neurodegenerative Diseases in 35 studies
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine is an aminoadamantane drug useful in neurodegenerative diseases, with beneficial effects on cognitive functions." | 3.77 | Effects of memantine, a non-competitive N-methyl-D-aspartate receptor antagonist, on genomic stability. ( Cappelari, SE; Flores, ÉM; Pereira, P; Picada, JN, 2011) |
| "Many drugs that have been developed to treat neurodegenerative diseases fail to gain approval for clinical use because they are not well tolerated in humans." | 2.44 | Pathologically activated therapeutics for neuroprotection. ( Lipton, SA, 2007) |
| "Glaucoma is a neurodegenerative disease for which the neuropathic pathology has been studied since 1972." | 2.44 | History of neuroprotection and rationale as a therapy for glaucoma. ( Levin, LA; Peeples, P, 2008) |
| "At present, the therapy of Alzheimer's disease is aimed at improving both, cognitive and behavioural symptoms and thereby, quality of life for the patients." | 2.43 | Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope. ( Kaul, CL; Ramarao, P; Sonkusare, SK, 2005) |
| "A cohort of 214 Alzheimer's disease (AD) patients was used as a neurodegenerative disease reference group." | 1.91 | Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease. ( Haapasalo, A; Hartikainen, P; Katisko, K; Krüger, J; Remes, AM; Solje, E; Soppela, H, 2023) |
| "Thymoquinone (TQ) has broad biological functions, including antiinflammatory, antioxidant, neuroprotective properties." | 1.91 | Effects of thymoquinone and memantine alone and in combination on memory and hippocampal morphology in rats with streptozotocin-induced Alzheimer's disease. ( Akçay, E; Çakir, Z; Gevrek, F; Özsoy, Ş, 2023) |
| "Contemporary methods of treatment of neurodegenerative diseases (NDs) are limited and mainly symptomatic." | 1.33 | [Mitochondria as the target for neuroprotectors]. ( Bachurin, SO; Kireeva, EG; Shevtsova, EF, 2005) |
| " These results indicate that antagonists of NMDA-type glutamate receptors are protective during the toxic outcome associated with mitochondrial dysfunction." | 1.33 | 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism. ( Bahr, BA; Baude, AS; Brown, QB; Karanian, DA; Parsons, CG, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 13 (37.14) | 24.3611 |
| 2020's | 11 (31.43) | 2.80 |
| Authors | Studies |
|---|---|
| Rook, Y | 1 |
| Schmidtke, KU | 1 |
| Gaube, F | 2 |
| Schepmann, D | 1 |
| Wünsch, B | 1 |
| Heilmann, J | 1 |
| Lehmann, J | 2 |
| Winckler, T | 2 |
| Huang, TL | 1 |
| Mayence, A | 1 |
| Vanden Eynde, JJ | 1 |
| Otto, R | 1 |
| Penzis, R | 1 |
| Adolph, O | 1 |
| Föhr, KJ | 1 |
| Warncke, P | 1 |
| Robaa, D | 1 |
| Appenroth, D | 1 |
| Fleck, C | 1 |
| Enzensperger, C | 1 |
| Lajarín-Cuesta, R | 1 |
| Nanclares, C | 1 |
| Arranz-Tagarro, JA | 1 |
| González-Lafuente, L | 1 |
| Arribas, RL | 1 |
| Araujo de Brito, M | 1 |
| Gandía, L | 1 |
| de Los Ríos, C | 1 |
| Świetlik, D | 1 |
| Kusiak, A | 1 |
| Ossowska, A | 1 |
| Wong, C | 1 |
| Dakin, RS | 1 |
| Williamson, J | 1 |
| Newton, J | 1 |
| Steven, M | 1 |
| Colville, S | 1 |
| Stavrou, M | 1 |
| Gregory, JM | 1 |
| Elliott, E | 1 |
| Mehta, AR | 1 |
| Chataway, J | 1 |
| Swingler, RJ | 1 |
| Parker, RA | 1 |
| Weir, CJ | 1 |
| Stallard, N | 1 |
| Parmar, MKB | 1 |
| Macleod, MR | 1 |
| Pal, S | 1 |
| Chandran, S | 1 |
| Majidazar, R | 1 |
| Rezazadeh-Gavgani, E | 1 |
| Sadigh-Eteghad, S | 1 |
| Naseri, A | 1 |
| Liu, M | 1 |
| Chen, C | 1 |
| Gao, K | 1 |
| Gao, F | 1 |
| Qin, C | 1 |
| Yuan, Q | 1 |
| Zhang, H | 1 |
| Zhuang, L | 1 |
| Wang, P | 1 |
| Perry, A | 1 |
| Hughes, LE | 1 |
| Adams, N | 1 |
| Naessens, M | 1 |
| Murley, AG | 1 |
| Rouse, MA | 1 |
| Street, D | 1 |
| Jones, PS | 1 |
| Cope, TE | 1 |
| Kocagoncu, E | 1 |
| Rowe, JB | 1 |
| Kapoor, T | 1 |
| Mehan, S | 1 |
| Suri, M | 1 |
| Sharma, N | 1 |
| Kumar, N | 1 |
| Narula, AS | 1 |
| Alshammari, A | 1 |
| Alasmari, AF | 1 |
| Alharbi, M | 1 |
| Assiri, MA | 1 |
| Kalfin, R | 1 |
| Painuli, S | 2 |
| Semwal, P | 2 |
| Zam, W | 2 |
| Taheri, Y | 2 |
| Ezzat, SM | 2 |
| Zuo, P | 2 |
| Li, L | 2 |
| Kumar, D | 2 |
| Sharifi-Rad, J | 2 |
| Cruz-Martins, N | 2 |
| Katisko, K | 1 |
| Krüger, J | 1 |
| Soppela, H | 1 |
| Hartikainen, P | 1 |
| Haapasalo, A | 1 |
| Remes, AM | 1 |
| Solje, E | 1 |
| You, FL | 1 |
| Xia, GF | 1 |
| Cai, J | 1 |
| Özsoy, Ş | 1 |
| Çakir, Z | 1 |
| Akçay, E | 1 |
| Gevrek, F | 1 |
| Shuvaev, AN | 2 |
| Belozor, OS | 1 |
| Mozhei, OI | 1 |
| Khilazheva, ED | 1 |
| Fritsler, YV | 1 |
| Kasparov, S | 1 |
| Kumar, A | 1 |
| Dejanovic, B | 1 |
| Hetsch, F | 1 |
| Semtner, M | 1 |
| Fusca, D | 1 |
| Arjune, S | 1 |
| Santamaria-Araujo, JA | 1 |
| Winkelmann, A | 1 |
| Ayton, S | 1 |
| Bush, AI | 1 |
| Kloppenburg, P | 1 |
| Meier, JC | 1 |
| Schwarz, G | 1 |
| Belaidi, AA | 1 |
| Müller, P | 1 |
| Fendt, M | 1 |
| Müller, NG | 1 |
| Hulme, SR | 1 |
| Jones, OD | 1 |
| Abraham, WC | 1 |
| Borre, YE | 1 |
| Panagaki, T | 1 |
| Koelink, PJ | 1 |
| Morgan, ME | 1 |
| Hendriksen, H | 1 |
| Garssen, J | 1 |
| Kraneveld, AD | 1 |
| Olivier, B | 1 |
| Oosting, RS | 1 |
| Kraft, JW | 1 |
| Zaja-Milatovic, S | 1 |
| Gupta, RC | 1 |
| Aschner, M | 1 |
| Milatovic, D | 1 |
| La Spada, AR | 1 |
| Nakamura, T | 1 |
| Lipton, SA | 4 |
| Flores, ÉM | 1 |
| Cappelari, SE | 1 |
| Pereira, P | 1 |
| Picada, JN | 1 |
| Iliffe, S | 1 |
| McGrath, T | 1 |
| Mitchell, D | 1 |
| Lo, D | 1 |
| Grossberg, GT | 1 |
| Sonkusare, SK | 1 |
| Kaul, CL | 1 |
| Ramarao, P | 1 |
| Shevtsova, EF | 1 |
| Kireeva, EG | 1 |
| Bachurin, SO | 1 |
| Karanian, DA | 1 |
| Baude, AS | 1 |
| Brown, QB | 1 |
| Parsons, CG | 2 |
| Bahr, BA | 1 |
| Wenk, GL | 2 |
| Danysz, W | 1 |
| Rosi, S | 1 |
| Vazdarjanova, A | 1 |
| Ramirez-Amaya, V | 1 |
| Worley, PF | 1 |
| Barnes, CA | 1 |
| Levin, LA | 1 |
| Peeples, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial[NCT04302870] | Phase 2/Phase 3 | 800 participants (Anticipated) | Interventional | 2020-02-27 | Recruiting | ||
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for memantine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Some non-conventional biomolecular targets for diamidines. A short survey.
Topics: Amidines; Animals; Diabetes Mellitus, Type 2; DNA; Enzymes; Humans; Hypertension; Ion Channels; Myot | 2014 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti- | 2022 |
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Memantine; N-Methylaspartate; Neurodegenerative Diseases; Receptors, N-Me | 2023 |
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Memantine; N-Methylaspartate; Neurodegenerative Diseases; Receptors, N-Me | 2023 |
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Memantine; N-Methylaspartate; Neurodegenerative Diseases; Receptors, N-Me | 2023 |
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Memantine; N-Methylaspartate; Neurodegenerative Diseases; Receptors, N-Me | 2023 |
[Drug treatment of Alzheimer's dementia : Status quo and perspectives].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memantine; Neurodegenerative Diseases | 2019 |
Emerging roles of metaplasticity in behaviour and disease.
Topics: Animals; Behavior; Behavior, Animal; Cognition Disorders; Conditioning, Classical; Gene Expression R | 2013 |
Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies.
Topics: Animals; Apoptosis; Calcium; Calcium Signaling; Excitatory Amino Acid Antagonists; Humans; Memantine | 2010 |
Use of memantine for the treatment of dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Humans; Indans; | 2011 |
Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Memantine; Neurodegenerative Diseases; | 2005 |
Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
Topics: Animals; Brain; Clinical Trials as Topic; Excitatory Amino Acid Antagonists; Humans; Memantine; Mode | 2004 |
Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine.
Topics: Alzheimer Disease; Animals; Brain; Cell Death; Excitatory Amino Acid Antagonists; Glutamic Acid; Hum | 2006 |
Pathologically activated therapeutics for neuroprotection.
Topics: Animals; Drug Delivery Systems; Excitatory Amino Acid Antagonists; Humans; Memantine; Neurodegenerat | 2007 |
History of neuroprotection and rationale as a therapy for glaucoma.
Topics: Disease Progression; Glaucoma; Humans; Memantine; Neurodegenerative Diseases; Neuroprotective Agents | 2008 |
1 trial available for memantine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Memantine; Motor Neuron Disease; Neurode | 2022 |
22 other studies available for memantine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
Topics: Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Excitatory Amino Ac | 2010 |
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
Topics: Animals; Carbolines; Cholinesterase Inhibitors; Computational Biology; Excitatory Amino Acid Antagon | 2015 |
Gramine Derivatives Targeting Ca(2+) Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases.
Topics: Alkaloids; Animals; Calcium Channels; Cattle; Cell Survival; Dose-Response Relationship, Drug; Hippo | 2016 |
Computational Modeling of Therapy with the NMDA Antagonist in Neurodegenerative Disease: Information Theory in the Mechanism of Action of Memantine.
Topics: Alzheimer Disease; Computer Simulation; Humans; Information Theory; Memantine; N-Methylaspartate; Ne | 2022 |
Neuronal network-based biomimetic chip for long-term detection of olfactory dysfunction model in early-stage Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomimetics; Biosensing Techniques; Dizocilpine Maleate; H | 2022 |
The neurophysiological effect of NMDA-R antagonism of frontotemporal lobar degeneration is conditional on individual GABA concentration.
Topics: Cross-Over Studies; Double-Blind Method; Frontotemporal Dementia; Frontotemporal Lobar Degeneration; | 2022 |
Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis.
Topics: Adenylyl Cyclases; Animals; Colforsin; Cytokines; Demyelinating Diseases; Donepezil; Ethidium; Fingo | 2022 |
Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.
Topics: Alzheimer Disease; Delayed Diagnosis; Female; Frontotemporal Dementia; Humans; Memantine; Neurodegen | 2023 |
Behavioural Variant Frontotemporal Dementia due to
Topics: Aged; Amyotrophic Lateral Sclerosis; Cyclins; Frontotemporal Dementia; Humans; Male; Memantine; Muta | 2023 |
Effects of thymoquinone and memantine alone and in combination on memory and hippocampal morphology in rats with streptozotocin-induced Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Hippocampus; Male; Maze Learning; Memantine; Neu | 2023 |
Protective Effect of Memantine on Bergmann Glia and Purkinje Cells Morphology in Optogenetic Model of Neurodegeneration in Mice.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Memantine; Mice; Neurodegenerative Diseases; Neuro | 2021 |
S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency.
Topics: Animals; Calcium Signaling; Cysteine; Disease Models, Animal; GABAergic Neurons; HEK293 Cells; Human | 2017 |
Neuroprotective and cognitive enhancing effects of a multi-targeted food intervention in an animal model of neurodegeneration and depression.
Topics: Animals; Atrophy; Cell Death; Cognition Disorders; Depressive Disorder; Disease Models, Animal; Hipp | 2014 |
[Drug treatment of dementia].
Topics: Antidepressive Agents; Cholinesterase Inhibitors; Dementia; Dose-Response Relationship, Drug; Drug A | 2017 |
Protection of DFP-induced oxidative damage and neurodegeneration by antioxidants and NMDA receptor antagonist.
Topics: Animals; Antioxidants; Biomarkers; Brain; Cholinesterase Inhibitors; Cyclic N-Oxides; Disease Models | 2009 |
Memantine strikes the perfect balance.
Topics: Excitatory Amino Acid Antagonists; Humans; Memantine; Neurodegenerative Diseases | 2009 |
Effects of memantine, a non-competitive N-methyl-D-aspartate receptor antagonist, on genomic stability.
Topics: Animals; Antioxidants; Brain; Comet Assay; DNA Damage; Dose-Response Relationship, Drug; Genomic Ins | 2011 |
The impact of patient and public involvement in the work of the Dementias & Neurodegenerative Diseases Research Network (DeNDRoN): case studies.
Topics: Alzheimer Disease; Biomedical Research; Community Participation; Dementia; Donepezil; Humans; Indans | 2013 |
Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Topics: Alzheimer Disease; Apoptosis; Brain; Calcium Channels; Cell Death; Clinical Trials as Topic; Cogniti | 2004 |
[Mitochondria as the target for neuroprotectors].
Topics: Animals; Antiparkinson Agents; Brain; Cell Death; Cells, Cultured; Dopamine Agents; Ginkgo biloba; I | 2005 |
3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism.
Topics: Animals; Animals, Newborn; Cytoskeleton; Dose-Response Relationship, Drug; Excitatory Amino Acid Ant | 2006 |
Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat.
Topics: Animals; Behavior, Animal; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship | 2006 |